Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP incubator, today announced that its subsidiary, Resurgent Biosciences, Inc. (“Resurgent”), is actively recruiting 100 participants to take part in an anonymous online survey to research the varying effects of entheogen and psychedelic experiences for therapeutic, religious, or spiritual purposes. The research will help inform Resurgent on future developments including research and wellness applications designed to help promote more positive, long-lasting outcomes from psychedelic-based therapies.


Goodness Growth Holdings (CSE: GDNS; OTCQX: GDNSF) is the new parent company of Vireo Health and Green Goods.

Existing research into the therapeutic use of psychedelics has focused heavily on synthetic substances, such as LSD, Ketamine, and MDMA, performed in controlled clinical settings. The survey being conducted by Resurgent, which has received approval from an independent Institutional Review Board (“IRB”) registered with the Office for Human Research Protections (“OHRP”), will instead focus on the naturalistic use of entheogens and other substances typically used in specific cultural and spiritual contexts for healing.

“Entheogens” refers to traditional substances, more commonly referred to as psychedelics, of fully natural origin and ingested to impact one’s consciousness for therapeutic, religious, or spiritual purposes. This is an innovative, first-of-its-kind survey delving into some key questions surrounding entheogen usage.

“Lab-based research will always be an essential aspect of our research and development process. However, to create more effective psychedelic-based therapies and services, we believe it is equally important to thoroughly explore the tremendous wealth of experience and wisdom that already exists and is active today based on centuries of both spiritual and therapeutic practices,” said Chief Medical Officer Stephen Dahmer , MD. “Learning from and respecting the rich history of psychedelic traditional practices as well as the extensive existing therapeutic use is an important first step to support a path for future therapies in the United States that afford long term safety and efficacy.”

To conduct this research, Resurgent will be performing an observational pilot survey, collecting self-reported, anonymous data from 100 adults who self-report having participated in entheogen therapy centers and retreats during the last five years on topics including their initial intentions, motivations, experiences, demographics, and willingness to participate in future entheogen research.

By collecting information from psychedelic-related ceremonies and retreats across the world, and particularly in South America , Resurgent aims to gain a greater understanding of these experiences and their impact on participants to develop better approaches for psychedelic-focused therapy and counselling.

“As a science-focused company, research remains the first and most important step in the development of new therapeutic approaches and supportive solutions related to psychedelics,” said Chairman and Chief Executive Officer, Kyle Kingsley , M.D. “As we work to further our understanding and acceptance of psychedelic-based therapies as beneficial, an IRB-approved research study will enable us to gather meaningful data to refine and focus our approach to development of products related to psychedelics therapy.”

The research study is being conducted through a partnership with Flor da Jurema , a temple community in Brazil , where visitors can practice traditional forms of plant-based medicines and take part in spiritual experiences around the globe.

To learn more, please visit the study’s page on the National Institute of Health’s Clinical Trials Website .

To participate in this study, visit https://redcap.link/SERPNTS .

About Goodness Growth Holdings, Inc.

Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world. The Company’s operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, Inc., and its science and intellectual property incubator, Resurgent Biosciences, Inc. The Company manufactures proprietary, branded cannabis products in environmentally friendly facilities and state-of-the-art cultivation sites and distributes its products through its growing network of Green Goods ® and other retail locations and third-party dispensaries. Its team of more than 500 employees are focused on the development of differentiated products, driving scientific innovation of plant-based medicines, and developing meaningful intellectual property. Today, the Company is licensed to grow, process, and/or distribute cannabis in eight markets and operates 18 dispensaries across the United States . For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com .

Contact Information

Investor Inquiries:

Media Inquiries:

Sam Gibbons

Albe Zakes

Vice President, Investor Relations

Vice President, Corporate Communications

samgibbons@goodnessgrowth.com

albezakes@goodnessgrowth.com

(612) 314-8995

(267) 221-4800

Cision View original content: https://www.prnewswire.com/news-releases/goodness-growth-holdings-subsidiary-resurgent-biosciences-launches-first-irb-approved-research-study-on-entheogens–psychedelic-experiences-301376158.html

SOURCE Goodness Growth Holdings

News Provided by PR Newswire via QuoteMedia

 

Cannabis Market Could Reach $5.5B By End Of Year

 
Experts Weigh In On Our Exclusive FREE Report. Can You Afford To Miss Out?
 

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or “the Company”) is pleased to announce that it is partnering with Loud Buddha Trimming to provide processing services to 3rd party growers out of its Daly Facility in Modesto, California.

TransCanna subsidiary Lyfted Farms has signed a Letter of Intent with Loud Buddha Trimming to jointly offer processing services like drying, hand trimming, curing, manicuring, machine trimming, bulk and retail packaging, pre-roll production and packaging, and storage of fresh-frozen biomass for concentrate production.

Keep reading... Show less

 Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company”), an established Canadian cannabis and vape retailer, announced today that its wholly-owned subsidiary, Spyder Cannabis Subco Inc. (“Spyder Subco”), has received Retail Store Authorization (“RSA”) from the Alcohol and Gaming Commission of Ontario (“AGCO”) for its proposed cannabis dispensary located at 767 Taunton Road in Oshawa, Ontario.

Furthermore, Spyder Subco has successfully passed a pre-authorization inspection with the AGCO and has now been placed in the queue to receive RSA on its second proposed cannabis dispensary in Niagara Falls, Ontario located at 5719 Victoria Avenue. Both retail premises will continue to operate as vape stores under the 180 Smoke banner name until the Company has finalized its new cannabis dispensary brand and banner name, which is expected to be finalized and announced in the coming weeks. The Company is exploring additional opportunities to convert other 180 Smoke retail locations – leveraging the brand’s current customer base of over 230,000 registered accounts – continuing to build and expand on Spyder’s footprint and presence in Ontario.

Keep reading... Show less

Combination Therapy with Psilocybin plus NAC (N-Acetylcysteine) Is Statistically Significantly Better Than Either Agent Alone or Placebo in a Rodent Model of mTBI and PTSD

Lobe Sciences Ltd. (” Lobe ” or the ” Company “) (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce interim data from its preclinical research studies, in established rodent models of mild traumatic brain injuryconcussion (“mTBI”) and post-traumatic stress disorder (“PTSD”), using psilocybin plus N-Acetylcysteine (“NAC”). The study is being conducted in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the leadership of Michael E. Hoffer M.D., professor of otolaryngology and neurological surgery.

Keep reading... Show less

A recently released cannabis report indicates that new formulations will be needed to satisfy changing consumer styles and demands.

The report from the EY Cannabis in Canada team outlines the rapidly changing cannabis landscape, and explains that the companies out there today need to stay active to be prepared for what’s ahead.

Keep reading... Show less

NASDAQ | TSX: ACB

  • #1 Canadian LP in Global Medical Cannabis; Total Medical Cannabis Net Revenue Rose 9% Compared to Prior Year; Strong Adjusted Gross Margin before FVA of 68%
  • Business Transformation Plan on Track; Reiterates Annual Cost Savings of $60 Million to $80 Million , Providing Clear Pathway to Adjusted EBITDA Profitability
  • Balance Sheet Remains Strong with $440.9 Million of Cash at June 30, 2021 ; Working Capital Improves by $404.3 Million Compared to Prior Year
  • Adjusted EBITDA Loss, Excluding Restructuring Costs, Narrows to $13.9 Million , a $17.6 Million Improvement Compared to Prior Year
  • Total Cannabis Net Revenue, Net of Provisions, of $54.8 Million Compared to $55.2 Million in the Prior Quarter, and $67.5 Million in the Year-Ago Period

 Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced its financial and operational results for the fourth quarter and full year fiscal 2021 ended June 30, 2021 .

Keep reading... Show less